bevacizumab,panitumumab
amgen,roche,takeda
['bevacizumab', 'panitumumab', 'crc,(-ccrcc),(-tbcrc049),(-mccrcc),(-mbcrc)', 'paradigm', 'beva']
db04 might have stole the show during the excellent #asco22 plenary today, but in head-to-head competition in paradigm the egfr mab panitumumab improved os (not pfs) over bevacizumab in combo with mfolfox6 as 1st-line therapy for ras wt left-sided metastatic #crc 
CME experts Sara Fagerlie, PhD, CHCP and Mindy Tanzola, PhD founded Front Row CME to help clinicians and educators manage the oncology information deluge.